You are here

A Nano-pharmaceutical Platform for Creating Artificial Vaccines

Award Information
Agency: Department of Defense
Branch: Defense Health Agency
Contract: W911NF-13-C-0044
Agency Tracking Number: O2-1303
Amount: $749,918.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: OSD11-H01
Solicitation Number: 2011.1
Timeline
Solicitation Year: 2011
Award Year: 2013
Award Start Date (Proposal Award Date): 2013-05-21
Award End Date (Contract End Date): 2015-05-21
Small Business Information
11260 Roger Bacon Drive Suite 406
Reston, VA -
United States
DUNS: 828881305
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Steven Armentrout
 CEO
 (703) 689-9689
 steve@parabon.com
Business Contact
 Paula Gawthorp-Armentrout
Title: Corporate Officer
Phone: (703) 689-9689
Email: parmentrout@parabon.com
Research Institution
 Stub
Abstract

In this project, Parabon NanoLabs will employ its Essemblix(tm) Drug Development Platform, a combination of computer-aided design (CAD) software and DNA nano-fabrication technology, to produce artificial vaccines against the biothreat agent ricin on DNA origami decorated first with natural epitopes and ultimately with artificial epitotopes (hereafter"mimotope") constructed from a predefined set of"building block molecules."Although this project focuses on a single biothreat agent, the ultimate goal is to advance the Essemblix technology such that, given an epitope for a potential biothreat agent, Essemblix will allow the production of mimotopes that can mimic the original epitope sufficiently to bind target antibodies with high affinity. In Phase I, we demonstrated Essemblix enables building block molecules to be arranged on origami in complex presentation patterns of the variety known to elicit rapid and potent immune response via T cell-independent activation and these techniques will be applied in Phase II. The resultant artificial vaccines, produced with natural and artificial epitopes, will be evaluated in murine studies to test their immunogenecity and toxicity, and a lead compound will be selected for further study, culminating in a demonstration of potency with lethal ricin challenge in mouse.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government